Financial Gravity Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Financial Gravity Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$1K	Buy	+63	New	+$932	0.31%	14
2019 Q4	–	Sell	-95	Closed	-$2K	–	1776
2019 Q3	$2K	Buy	95 +39	+70%	+$894	﹤0.01%	945
2019 Q2	$2K	Sell	56 -26	-32%	-$1K	﹤0.01%	970
2019 Q1	$4K	Buy	+82	New	+$3.61K	﹤0.01%	791

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Financial Gravity Asset Management's AERI Position: Q2 2020 in Review

Financial Gravity Asset Management opened a new position in Aerie Pharmaceuticals (AERI) in Q2 2020: 63 shares worth $1K. The stake represents 0.31% of the portfolio and ranks #14 among its holdings. This is a return to the name: Financial Gravity Asset Management previously reported a position in AERI as recently as Q3 2019.

Financial Gravity Asset Management first reported a position in AERI in Q1 2019 and has held it in 4 quarters since. The position peaked at $4K in Q1 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Financial Gravity Asset Management held 63 shares of Aerie Pharmaceuticals worth $1K as of Q2 2020.
Aerie Pharmaceuticals was a new Financial Gravity Asset Management position in Q2 2020.
Aerie Pharmaceuticals made up 0.31% of Financial Gravity Asset Management's portfolio in Q2 2020, its #14 holding.
Financial Gravity Asset Management first reported a position in Aerie Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
Financial Gravity Asset Management's Aerie Pharmaceuticals position peaked at $4K in Q1 2019.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Financial Gravity Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.